✓
Open
25 Apr 2023
✓
Close
27 Apr 2023
3
Allotment
—
✓
Listing
Tue, May 9, 2023
Price Band
₹1026 to ₹1080
Issue Size
4,00,58,844 shares (agg. up to ₹4,326 Cr)
Lot Size
13 Shares
Listing Date
Tue, May 9, 2023
Latest GMP
₹121
Est. Gain
11.2%
✦ AI Insight
GMP Trend
09-05-2023₹121Est. ₹1201+11.2%
08-05-2023₹140Est. ₹1220+12.96%
07-05-2023₹113Est. ₹1193+10.46%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 11.01x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Dec 2022 | 31 Mar 2022 | 31 Dec 2021 | 31 Mar 2021 | 31 Mar 2020 |
|---|---|---|---|---|---|
| Assets | 9,273.75 | 9,147.74 | 8,043.88 | 6,372.63 | 5,073.29 |
| Total Income | 6,777.82 | 7,977.58 | 6,218.29 | 6,385.38 | 5,975.65 |
| Profit After Tax | 1,015.98 | 1,452.96 | 1,260.24 | 1,293.03 | 1,056.15 |
| NET Worth | 7,145.89 | 6,155.23 | 5,965.46 | 4,722.00 | 3,485.31 |
| Reserves and Surplus | 7,094.12 | 6,106.06 | 5,916.86 | 4,674.39 | 3,436.34 |
| Total Borrowing | 167.93 | 868.03 | 268.70 | 234.53 | 126.92 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Infinium Pharmachem Ltd. | SME | ₹25.25 Cr | ₹135 | 7.83 | ₹147.80 | +9.48% | ₹206.05 (-3.04%) |
| Sotac Pharmaceuticals Ltd. | SME | ₹33.30 Cr | ₹111 | 132.14 | ₹120.75 | +8.78% | ₹95.10 (-4.90%) |
| Trident Lifeline Ltd. | SME | ₹35.34 Cr | ₹101 | 51.53 | ₹108.15 | +7.08% | ₹260.90 (+1.89%) |
| Dipna Pharmachem Ltd. | SME | ₹15.21 Cr | ₹38 | 39 | ₹33.40 | -12.11% | ₹5.40 (-0.74%) |
| JFL Life Sciences Ltd. | SME | ₹18.17 Cr | ₹61 | 26.52 | ₹66.50 | +9.02% | ₹11.00 (+3.77%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Carry out the Offer for Sale of 40,058,844Equity Shares by the Selling Shareholders aggregating to ₹43,263.55 million | |
| 2 | Achieve the benefits of listing the Equity Shares on the Stock Exchanges. For further details |
About Mankind Pharma IPO
Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products. In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them. Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market. Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022. The company has earned numerous awards and recognitions and including The Best of Bharat Awards 2022 by exchange4media in the year 2022, and Silver Medal from National Awards for Manufacturing Competitivenes
Contact Details
Mankind Pharma Ltd. Address208, Okhla Industrial EstatePhase-IIINew Delhi, New Delhi, 110020+91 11 4684 6700investors@mankindpharma.comVisit Website